Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers (ARB) alone showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin receptor blockers (ARB) alone showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors showed no clear difference in fatal or nonfatal stroke Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin receptor blockers (ARB) alone showed no clear difference in fatal or nonfatal myocardial infarction Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
Angiotensin receptor blockers (ARB) alone showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
1 finding from 1 review
Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease
Angiotensin receptor blockers (ARB) alone showed no clear difference in micro‐ to normoalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
1 finding from 1 review
Death (any cause) (median · people with diabetes and kidney disease
1 finding from 1 review
Cardiovascular death4 Median · people with diabetes and kidney disease
1 finding from 1 review
Doubling of SCr · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatal or nonfatal stroke · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Micro‐ to macroalbuminuria · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Micro‐ to normoalbuminuria · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors showed no clear difference in fatal or nonfatal myocardial infarction Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
It is very uncertain whether angiotensin receptor blocker (ARB) changes all‐cause death Median compared with another ARB (very low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in cardiovascular death Median compared with another ARB (low certainty).
1 finding from 1 review
Doubling of SCr4 · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in doubling of SCr4 compared with another ARB (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in fatal or nonfatal stroke6 compared with another ARB (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in fatal or nonfatal myocardial infarction7 compared with another ARB (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria · people with diabetes and kidney disease
Angiotensin receptor blocker (ARB) showed no clear difference in micro‐ to macroalbuminuria 8 compared with another ARB (low certainty).
1 finding from 1 review